Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy DrReddys Laboratories stock | $63.84

Learn how to easily invest in DrReddys Laboratories stock.

Dr. Reddy's Laboratories Limited is a drug manufacturers-specialty & generic business based in the US. DrReddys Laboratories shares (RDY) are listed on the NYSE and all prices are listed in US Dollars. DrReddys Laboratories employs 22,739 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in DrReddys Laboratories

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RDY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

DrReddys Laboratories stock price (NYSE: RDY)

Use our graph to track the performance of RDY stocks over time.

DrReddys Laboratories shares at a glance

Information last updated 2021-10-17.
Latest market close$63.84
52-week range$56.97 - $74.75
50-day moving average $65.67
200-day moving average $68.00
Wall St. target price$77.85
PE ratio 48.0073
Dividend yield $25 (38.19%)
Earnings per share (TTM) $1.38

Buy DrReddys Laboratories shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DrReddys Laboratories stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DrReddys Laboratories price performance over time

Historical closes compared with the close of $63.84 from 2021-10-19

1 week (2021-10-13) -1.34%
1 month (2021-09-20) -1.83%
3 months (2021-07-20) -10.83%
6 months (2021-04-20) -5.23%
1 year (2020-10-20) -6.78%
2 years (2019-10-18) 64.92%
3 years (2018-10-19) 83.92%
5 years (2016-10-20) 38.60%

Is DrReddys Laboratories under- or over-valued?

Valuing DrReddys Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DrReddys Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DrReddys Laboratories's P/E ratio

DrReddys Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, DrReddys Laboratories shares trade at around 48x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

DrReddys Laboratories's PEG ratio

DrReddys Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6592. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DrReddys Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

DrReddys Laboratories's EBITDA

DrReddys Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $43.2 billion.

The EBITDA is a measure of a DrReddys Laboratories's overall financial performance and is widely used to measure a its profitability.

DrReddys Laboratories financials

Revenue TTM $194.7 billion
Operating margin TTM 16.15%
Gross profit TTM $103.1 billion
Return on assets TTM 7.42%
Return on equity TTM 10.09%
Profit margin 8.81%
Book value $1,074.08
Market capitalisation $11 billion

TTM: trailing 12 months

Shorting DrReddys Laboratories shares

There are currently 975,394 DrReddys Laboratories shares held short by investors – that's known as DrReddys Laboratories's "short interest". This figure is 14.9% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting DrReddys Laboratories shares can be evaluated.

DrReddys Laboratories's "short interest ratio" (SIR)

DrReddys Laboratories's "short interest ratio" (SIR) is the quantity of DrReddys Laboratories shares currently shorted divided by the average quantity of DrReddys Laboratories shares traded daily (recently around 112632.10161663). DrReddys Laboratories's SIR currently stands at 8.66. In other words for every 100,000 DrReddys Laboratories shares traded daily on the market, roughly 8660 shares are currently held short.

However DrReddys Laboratories's short interest can also be evaluated against the total number of DrReddys Laboratories shares, or, against the total number of tradable DrReddys Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DrReddys Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 DrReddys Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0083% of the tradable shares (for every 100,000 tradable DrReddys Laboratories shares, roughly 8 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against DrReddys Laboratories.

Find out more about how you can short DrReddys Laboratories stock.

DrReddys Laboratories share dividends


Dividend payout ratio: 21.65% of net profits

Recently DrReddys Laboratories has paid out, on average, around 21.65% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.51% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), DrReddys Laboratories shareholders could enjoy a 0.51% return on their shares, in the form of dividend payments. In DrReddys Laboratories's case, that would currently equate to about $25 per share.

While DrReddys Laboratories's payout ratio might seem low, this can signify that DrReddys Laboratories is investing more in its future growth.

DrReddys Laboratories's most recent dividend payout was on 10 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 7 July 2021 (the "ex-dividend date").

Have DrReddys Laboratories's shares ever split?

DrReddys Laboratories's shares were split on a 2:1 basis on 6 September 2006. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your DrReddys Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for DrReddys Laboratories shares which in turn could have impacted DrReddys Laboratories's share price.

DrReddys Laboratories share price volatility

Over the last 12 months, DrReddys Laboratories's shares have ranged in value from as little as $56.9679 up to $74.7492. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while DrReddys Laboratories's is 0.0987. This would suggest that DrReddys Laboratories's shares are less volatile than average (for this exchange).

DrReddys Laboratories overview

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.

Frequently asked questions

What percentage of DrReddys Laboratories is owned by insiders or institutions?
Currently 0.012% of DrReddys Laboratories shares are held by insiders and 11.383% by institutions.
How many people work for DrReddys Laboratories?
Latest data suggests 22,739 work at DrReddys Laboratories.
When does the fiscal year end for DrReddys Laboratories?
DrReddys Laboratories's fiscal year ends in March.
Where is DrReddys Laboratories based?
DrReddys Laboratories's address is: 8-2-337, Road No. 3, Hyderabad, India, 500034
What is DrReddys Laboratories's ISIN number?
DrReddys Laboratories's international securities identification number is: US2561352038
What is DrReddys Laboratories's CUSIP number?
DrReddys Laboratories's Committee on Uniform Securities Identification Procedures number is: 256135203

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site